File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1371/journal.pone.0025547
- Scopus: eid_2-s2.0-80053161961
- PMID: 21966542
- WOS: WOS:000295932100050
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Nuclear-targeted deleted in liver cancer 1 (DLC1) is less efficient in exerting its tumor suppressive activity both in vitro and in vivo
Title | Nuclear-targeted deleted in liver cancer 1 (DLC1) is less efficient in exerting its tumor suppressive activity both in vitro and in vivo | ||||||
---|---|---|---|---|---|---|---|
Authors | |||||||
Issue Date | 2011 | ||||||
Publisher | Public Library of Science. The Journal's web site is located at http://www.plosone.org/home.action | ||||||
Citation | PLoS One, 2011, v. 6 n. 9, article no. e25547 How to Cite? | ||||||
Abstract | BACKGROUND: Deleted in liver cancer 1 (DLC1) serves as an important RhoGTPase activating protein (RhoGAP) protein that terminates active RhoA signaling in human cancers. Increasing evidence has demonstrated that the tumor suppressive activity of DLC1 depends not only on RhoGAP activity, but also relies on proper focal adhesion localization through its interaction with tensin family proteins. Recently, there are reports showing that DLC1 can also be found in the nucleus; however, the existence and the relative tumor suppressive activity of nuclear DLC1 have never been clearly addressed. METHODOLOGY AND PRINCIPAL FINDINGS: We herein provide new evidence that DLC1 protein, which predominantly associated with focal adhesions and localized in cytosol, dynamically shuttled between cytoplasm and nucleus. Treatment of cells with nuclear export blocker, Leptomycin B (LMB), retained DLC1 in the nucleus. To understand the nuclear entry of DLC1, we identified amino acids 600-700 of DLC1 as a novel region that is important for its nuclear localization. The tumor suppressive activity of nuclear DLC1 was directly assessed by employing a nuclear localization signal (NLS) fusion variant of DLC1 (NLS-DLC1) with preferential nuclear localization. In SMMC-7721 HCC cells, expression of NLS-DLC1 failed to suppress colony formation and actin stress fiber formation in vitro. The abrogated tumor suppressive activity of nuclear DLC1 was demonstrated for the first time in vivo by subcutaneously injecting p53(-/-) RasV12 hepatoblasts with stable NLS-DLC1 expression in nude mice. The injected hepatoblasts with NLS-DLC1 expression effectively formed tumors when compared with the non-nuclear targeted DLC1. CONCLUSIONS/SIGNIFICANCE: Our study identified a novel region responsible for the nuclear entry of DLC1 and demonstrated the functional difference of DLC1 in different cellular compartments both in vitro and in vivo. | ||||||
Persistent Identifier | http://hdl.handle.net/10722/148649 | ||||||
ISSN | 2023 Impact Factor: 2.9 2023 SCImago Journal Rankings: 0.839 | ||||||
PubMed Central ID | |||||||
ISI Accession Number ID |
Funding Information: This work was supported by the Hong Kong Research Grants Council (HKU7798/07M), Hong Kong Research Grants Council Collaborative Research Fund (HKU 1/06C and HKU 7/CRG/09) and Outstanding Young Researcher Award (to J.W.P. Yam). I.O.L. Ng is Loke Yew Professor in Pathology. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. | ||||||
References | |||||||
Grants |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chan, LK | en_US |
dc.contributor.author | Ko, FCF | en_US |
dc.contributor.author | Sze, KMF | en_US |
dc.contributor.author | Ng, IOL | en_US |
dc.contributor.author | Yam, JWP | en_US |
dc.date.accessioned | 2012-05-29T06:14:22Z | - |
dc.date.available | 2012-05-29T06:14:22Z | - |
dc.date.issued | 2011 | en_US |
dc.identifier.citation | PLoS One, 2011, v. 6 n. 9, article no. e25547 | en_US |
dc.identifier.issn | 1932-6203 | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/148649 | - |
dc.description.abstract | BACKGROUND: Deleted in liver cancer 1 (DLC1) serves as an important RhoGTPase activating protein (RhoGAP) protein that terminates active RhoA signaling in human cancers. Increasing evidence has demonstrated that the tumor suppressive activity of DLC1 depends not only on RhoGAP activity, but also relies on proper focal adhesion localization through its interaction with tensin family proteins. Recently, there are reports showing that DLC1 can also be found in the nucleus; however, the existence and the relative tumor suppressive activity of nuclear DLC1 have never been clearly addressed. METHODOLOGY AND PRINCIPAL FINDINGS: We herein provide new evidence that DLC1 protein, which predominantly associated with focal adhesions and localized in cytosol, dynamically shuttled between cytoplasm and nucleus. Treatment of cells with nuclear export blocker, Leptomycin B (LMB), retained DLC1 in the nucleus. To understand the nuclear entry of DLC1, we identified amino acids 600-700 of DLC1 as a novel region that is important for its nuclear localization. The tumor suppressive activity of nuclear DLC1 was directly assessed by employing a nuclear localization signal (NLS) fusion variant of DLC1 (NLS-DLC1) with preferential nuclear localization. In SMMC-7721 HCC cells, expression of NLS-DLC1 failed to suppress colony formation and actin stress fiber formation in vitro. The abrogated tumor suppressive activity of nuclear DLC1 was demonstrated for the first time in vivo by subcutaneously injecting p53(-/-) RasV12 hepatoblasts with stable NLS-DLC1 expression in nude mice. The injected hepatoblasts with NLS-DLC1 expression effectively formed tumors when compared with the non-nuclear targeted DLC1. CONCLUSIONS/SIGNIFICANCE: Our study identified a novel region responsible for the nuclear entry of DLC1 and demonstrated the functional difference of DLC1 in different cellular compartments both in vitro and in vivo. | en_US |
dc.language | eng | en_US |
dc.publisher | Public Library of Science. The Journal's web site is located at http://www.plosone.org/home.action | en_US |
dc.relation.ispartof | PLoS ONE | en_US |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject.mesh | Cell Line, Tumor | - |
dc.subject.mesh | Cell Nucleus - drug effects - metabolism | - |
dc.subject.mesh | Fatty Acids, Unsaturated - pharmacology | - |
dc.subject.mesh | GTPase-Activating Proteins - genetics - metabolism | - |
dc.subject.mesh | Tumor Suppressor Proteins - genetics - metabolism | - |
dc.title | Nuclear-targeted deleted in liver cancer 1 (DLC1) is less efficient in exerting its tumor suppressive activity both in vitro and in vivo | en_US |
dc.type | Article | en_US |
dc.identifier.email | Chan, LK: lkchan1@hku.hk | en_US |
dc.identifier.email | Ko, FCF: bokcf@hku.hk | en_US |
dc.identifier.email | Sze, KMF: karensze@hkucc.hku.hk | - |
dc.identifier.email | Ng, IOL: iolng@hku.hk | - |
dc.identifier.email | Yam, JWP: judyyam@pathology.hku.hk | - |
dc.identifier.authority | Ng, IOL=rp00335 | en_US |
dc.identifier.authority | Yam, JWP=rp00468 | en_US |
dc.description.nature | published_or_final_version | en_US |
dc.identifier.doi | 10.1371/journal.pone.0025547 | en_US |
dc.identifier.pmid | 21966542 | - |
dc.identifier.pmcid | PMC3180446 | - |
dc.identifier.scopus | eid_2-s2.0-80053161961 | en_US |
dc.identifier.hkuros | 201435 | - |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-80053161961&selection=ref&src=s&origin=recordpage | en_US |
dc.identifier.volume | 6 | en_US |
dc.identifier.issue | 9, article no. e25547 | en_US |
dc.identifier.isi | WOS:000295932100050 | - |
dc.publisher.place | United States | en_US |
dc.relation.project | Molecular pathology of liver cancer - a multidisciplinary study | - |
dc.identifier.issnl | 1932-6203 | - |